OOIR: Observatory of International Research

Papers

(The median citation count of Leukemia & Lymphoma is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma	43
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia	41
Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study	36
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults	35
Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025	35
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies	32
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies	30
Venetoclax is safe and efficacious in relapsed/refractory AML	30
Hematological manifestations of COVID-19	26
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature	25
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma	24
Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination	23
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*	22
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data	21
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia	21
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States	21
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome	21
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)	21
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells	21
lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p	21
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience	20
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib	20
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort	20
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience	20
Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia	19

Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway	19
Acute lymphoblastic leukemia mortality in Hispanic Americans	18
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study	18
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group	17
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	17
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima^®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience	17
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma	16
Low absolute CD4⁺ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma	16
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma	16
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas	16
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation	16
Pembrolizumab immunotherapy for relapsed CNS Lymphoma	16
Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists	16
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population	16
The effect of ibrutinib on neutrophil and γδ T cell functions	15
Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy	15
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis	15
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia	15
Long noncoding RNA LINC00467 facilitates the progression of acute myeloid leukemia by targeting the miR-339/SKI pathway	15
The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement	15
Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis	15
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma	15
Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas	15
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms	15
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors	15
Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia	14
Analysis and impact of a multidisciplinary lymphoma virtual tumor board	14
CD5+ diffuse large B-cell lymphoma: a narrative review	14
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice	14
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies	14
Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy	14
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome	14
Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult	13
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy	13
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia	13
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma	13
CAR-T cell persistence in the treatment of leukemia and lymphoma	13
The prognostic value of the controlling nutritional status score in patients with multiple myeloma	13
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD	13
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma	13
Management of myelofibrosis after ruxolitinib failure	12
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy	12
Selinexor for advanced hematologic malignancies	12
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax	12
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas	12
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia	12
Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies	12
The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy	12
Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib	12
Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study	12

Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas	12
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma	12
Efficacy and safety of weekly carfilzomib (70 mg/m²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study c	12
Novel therapeutics and targets in myelofibrosis	12
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections	12
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection	12
Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms	12
Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years	12
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma	12
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma	12
Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count	11
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes	11
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study	11
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory mul	11
Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL)	11
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial	11
Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia	11
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple m	11
The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor	11
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration	11
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program	11
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia	11
Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD	11
Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment	11
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia	11
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy	11
Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas	11
AML1-ETO inhibits acute myeloid leukemia immune escape by CD48	11
An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia	11
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series	11
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia	10
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia	10
Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort	10
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia	10
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience	10
Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma	10
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia	10
Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy	10
Idelalisib immune-related toxicity is associated with improved treatment response	10
Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation	10
Glofitamab CD20-TCB bispecific antibody	10
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	10
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma	10
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia	10
Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial	10
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study	10
The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis	10
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials	10
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database	10
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies	10
Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA^G17V and IDH2^R172 hot-spot mutations in plasma cell-free DNA as liquid	10
Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience	10
The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt	10
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience	10
The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients	9
Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4–Not deadenylase in non-Hodgkin lymphoma	9
Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes	9
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial	9
High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis	9
The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides	9
Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice	9
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	9
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas	9
Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome	9
Low-dose vemurafenib monotherapy in BRAF^V600E-mutated Erdheim-Chester disease	9
Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity	9
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia	9
Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada	9
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	9
The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine	9
A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia	9
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020	9
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy ^*	9
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions	9
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma	9
Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia	9
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements	9
Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK	8
Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients	8
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL	8

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study	8
Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy	8
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients	8
Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors	8
Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1	8
Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment	8
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression	8
Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia	8
Momelotinib reduces transfusion requirements in patients with myelofibrosis	8
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis	8
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia	8
Hyperleukocytosis and leukostasis in acute and chronic leukemias	8
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience	8
Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood	8
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin	8
Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW)	8
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees	8
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma	8
Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia	8
A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma	8
Wilms’ tumor 1 gene in hematopoietic malignancies: clinical implications and future directions	8
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia	8
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients	8
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma	8
Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation	8
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia	8
Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation	8
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance	8
Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features	8
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia	8
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis	7
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis	7
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?	7
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from	7
Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone	7
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy	7
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi	7
Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia	7
Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma	7
Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom	7
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia	7
Follicular lymphoma genomics	7
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients	7
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the	7
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy	7
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation	7
Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care	7
G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD	7
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia	7
Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia	7
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia	7
Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis	7
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis	7
Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China	7
Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?	7
Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation	7
Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells	7
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	7
Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population	7
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma	7
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma	7
Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study	7
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*	7
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis	7
The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification	7
Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman’s disease	7
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis	7
Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lym	7
Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells	7
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis	7
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management	7
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study	7
miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway	7
Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes	7
Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation	6
Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment	6
Artificial intelligence models in chronic lymphocytic leukemia – recommendations toward state-of-the-art	6
Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases	6
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients	6
Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant	6
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing	6
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia	6
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome	6
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality	6
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial	6
Primary refractory multiple myeloma: a real-world experience with 85 cases	6
Comorbidities cluster with impaired functional capacities and depressive mood and predict adverse outcome in older patients with hematological malignancies	6
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia	6
Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice	6
Specific TCR V–J gene segment recombinations leading to the identification pan-V–J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma	6
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study	6
Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab	6
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	6
CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies	6
The successful use of FLT3 inhibitors in FLT3-positive mixed phenotype acute leukemia	6